関連する実験動画
Updated: Sep 10, 2025

07:04
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
539
PD-1/PD-L1阻害抵抗を克服する戦略:免疫チェックポイント阻害との組み合わせに焦点を当てた
Dinglin Liu1,2, Haoyue Xiao2, Ying Xiang1,2
1Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434023, China.
Journal of Cancer
|August 27, 2025
まとめ
免疫チェックポイントブロック (ICB) はがん治療において有望ですが,抵抗性があります. このレビューでは,患者のアウトカムを改善するために,PD-1/PD-L1を他のICBと併用したレジスタンスメカニズムと組み合わせた治療法を調査します.
科学分野:
- 腫瘍学
- 免疫学
- ガン治療薬
背景:
- 免疫チェックポイント阻害 (ICB),特にPD-1/PD-L1阻害は,がん治療を進めて,進行中の耐火性腫瘍に利点をもたらしています.
- PD-1/ PD- L1 阻害の有効性は,低反応率と薬剤耐性により制限されており,さらなる調査が必要である.
研究 の 目的:
- 癌におけるPD-1/PD-L1阻害に対する耐性の基礎となる複雑なメカニズムの検討
- PD-1/ PD- L1 阻害と他の免疫チェックポイント阻害剤 (ICI) を併用して抵抗を克服する戦略を探求する.
主な方法:
- PD-1/PD-L1の阻害抵抗に寄与するメカニズムに関する文献レビュー
- CTLA-4,TIM-3,LAG-3,TIGIT,VISTAなどの他のICIとPD-1/PD-L1阻害を含む組み合わせ戦略の分析
主要な成果:
- 主な抵抗メカニズムには,エフェクターT細胞の欠如,標的PD-1/PD-L1発現の欠如,腫瘍免疫性の低下,免疫抑制性腫瘍微環境 (TME) が含まれる.
- 腫瘍の代謝,表遺伝的変化,腸内微生物群なども 耐性につながる要因です
- 治療後の代替免疫チェックポイントのアップレギュレーションは,組み合わせ治療のための潜在的なターゲットを示唆しています.
結論:
- PD-1/PD-L1阻害抵抗メカニズムの理解は,がん治療の有効性を改善するために不可欠です.
- 特に他のICIと組み合わせた治療は,様々ながんの治療効果を高め,耐性を克服するための有望な戦略です.
関連する概念動画
Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K

